Could a melanoma drug combo tame rare BRAF cancers?

NCT ID NCT05768178

Recruiting now Disease control Sponsor: Cancer Research UK Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial is testing two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific genetic change called BRAF V600 mutation. The goal is to see if the combination can shrink tumors or stop them from growing. About 30 people with various cancers like lung, ovarian, or thyroid cancer are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vemurafenib (Zelboraf) and cobimetinib (Cotellic)
What this could lead to: If successful, this could expand the use of an already-approved melanoma drug combination to treat other rare cancers with the same BRAF mutation, potentially offering a new option for patients with limited choices.
What could go wrong: This is an early-to-mid-stage trial with only 30 participants, so results may not apply broadly. The drugs can cause side effects like rash, nausea, and eye problems, and may not work for all cancer types tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal neoplasm Erdheim-Chester disease glioma hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm laryngeal neoplasm melanoma neoplasm Neoplasms by Histologic Type Neoplasms by Site non-small cell lung carcinoma ovarian cancer ovarian neoplasm plasma cell myeloma Thyroid Cancer, Papillary thyroid gland papillary carcinoma thyroid gland undifferentiated (anaplastic) carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG COLORECTAL NEOPLASMS ERDHEIM-CHESTER DISEASE GLIOMA HAEMATOLOGICAL MALIGNANCY LARYNGEAL NEOPLASMS MELANOMA MULTIPLE MYELOMA OVARIAN NEOPLASMS SOLID TUMOUR THYROID CANCER, PAPILLARY THYROID CARCINOMA, ANAPLASTIC

Contacts and locations

Locations

Addenbrooke's Hospital
RECRUITING

Cambridge, CB2 OQQ, United Kingdom
Belfast City Hospital
RECRUITING

Belfast, BT9 7AB, United Kingdom
Bristol Haematology and Oncology Centre
RECRUITING

Bristol, BS2 8ED, United Kingdom
Churchill Hospital
RECRUITING

Oxford, OX3 7LE, United Kingdom
Clatterbridge Cancer Centre
RECRUITING

Metropolitan Borough of Wirral, CH63 4JY, United Kingdom
Freeman Hospital
RECRUITING

Newcastle, NE7 7DN, United Kingdom
Guy's Hospital
RECRUITING

London, SE1 9RT, United Kingdom
Leicester Royal Infirmary
RECRUITING

Leicester, LE1 5WW, United Kingdom
Southampton General Hospital
RECRUITING

Southampton, SO16 6YD, United Kingdom
The Beatson Hospital
RECRUITING

Glasgow, G12 OYN, United Kingdom
The Christie Hospital
RECRUITING

Manchester, M20 4BX, United Kingdom
University College London Hospital
RECRUITING

London, NW1 2BU, United Kingdom
University Hospital Birmingham
RECRUITING

Birmingham, B15 2TT, United Kingdom
Velindre Cancer Centre
RECRUITING

Cardiff, CF14 2TL, United Kingdom
Western General Hospital
RECRUITING

Edinburgh, EH4 2XU, United Kingdom
Weston Park Hospital
RECRUITING

Sheffield, S10 2SJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.